Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Unknown 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 66Recurrence 20Neoplasms, Plasma Cell 8Primary Myelofibrosis 3Polycythemia Vera 3Myeloproliferative Disorders 3Renal Insufficiency 2Plasmacytoma 2Lymphoma, Non-Hodgkin 2Immunoglobulin Light-chain Amyloidosis 2Central Nervous System Neoplasms 2Waldenstrom Macroglobulinemia 1Unspecified Adult Solid Tumor, Protocol Specific 1Thrombocytosis 1Thrombocythemia, Essential 1Sarcoma, Kaposi 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Optic Nerve Glioma 1Neurofibromatosis 1 1Neoplasms 1Medulloblastoma 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Leukemia, Megakaryoblastic, Acute 1Intraocular Lymphoma 1Hodgkin Disease 1Glioma 1

Interventions

Lenalidomide 4Bortezomib 4Dexamethasone 3vandetanib 2tumor necrosis factor-alpha, CNGRC fusion protein, human 2liposomal doxorubicin 2Doxorubicin 2tremelimumab 1tivozanib 1ricolinostat 1pomalidomide 1pazopanib 1nilotinib 1durvalumab 1avelumab 1abexinostat 1Transplantation, Autologous 1Tamoxifen 1Steroids 1Standard of Care 1Practice Guidelines as Topic 1Parenteral Nutrition 1Palliative Care 1Paclitaxel 1Nivolumab 1NVP-BKM120 1Melphalan 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Filgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Disease Progression × pomalidomide × Clear all
NCT02189343 2019-11-21

Phase 1b Study Evaluating ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1 Completed
16 enrolled
Plasma cell

Disease, Multiple Myeloma, Recurrence, Disease Progression

Data powered by HemOnc (CC BY 4.0) Colophon âš¡